Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells $470,998.43 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna sold 17,647 shares of the business’s stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $26.69, for a total transaction of $470,998.43. Following the completion of the transaction, the chief accounting officer now owns 32,546 shares of the company’s stock, valued at approximately $868,652.74. This represents a 35.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ KNSA opened at $26.09 on Monday. The firm has a market cap of $1.90 billion, a PE ratio of -186.34 and a beta of 0.07. The firm has a fifty day moving average of $22.40 and a 200 day moving average of $21.30. Kiniksa Pharmaceuticals, Ltd. has a one year low of $17.38 and a one year high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. During the same quarter in the prior year, the firm earned ($0.25) earnings per share. The company’s revenue for the quarter was up 72.5% compared to the same quarter last year. On average, equities analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on KNSA shares. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, April 29th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average price target of $38.80.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in shares of Kiniksa Pharmaceuticals by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after purchasing an additional 568 shares in the last quarter. US Bancorp DE acquired a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth about $33,000. Asset Management One Co. Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth about $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth about $42,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth about $61,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.